With JPMorgan's overweight rating and an $80 price target indicating over 40% potential upside, I'm feeling bullish on Viking Therapeutics. The upcomi...
Read More
With JPMorgan's overweight rating and an $80 price target indicating over 40% potential upside, I'm feeling bullish on Viking Therapeutics. The upcoming data readout in November could serve as a strong catalyst, and I want to position myself ahead of that news.